May 9th 2024
In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
N-803 in Combination With BCG Yields Encouraging Responses in BCG-Unresponsive Bladder Cancer
September 10th 2021Patients with BCG-unresponsive, non-muscle invasive bladder cance carcinoma in situ had promising responses to Bacille Calmette-Guérinplus N-803, updated data from cohort A of the phase 2/3 QUILT-3.032 study.
Read More
Elevated Antibody Titers May Be a Prognostic Marker in BCG-Unresponsive NMIBC
September 10th 2021According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.
Read More
Buparlisib Treatment Begins in Combination With AN0025 and Atezolizumab for Advanced Solid Tumors
September 9th 2021The first patient with a locally advanced or metastatic solid tumor has been dosed with buparlisib in combination with A0025 with or without atezolizumab in a phase 1a clinical trial.
Read More
Study Explores Sacituzumab Goveitecan Versus SOC in Metastatic or Locally Advanced Unresectable UC
August 30th 2021Sacituzumab goveitecan has been administered to the first time in a patient with metastatic or locally advanced unresectable urothelial carcinoma as part of the phase TROPICS-04 study.
Read More
FDA Approves Adjuvant Nivolumab for Surgically Resected, High-Risk Bladder Cancer
August 20th 2021The FDA has granted approval to nivolumab as an adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing radical resection, regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status.
Read More
MRD Assay Is New Step in Urothelial Cancer Testing
August 13th 2021A post hoc analysis from the IMvigor010 study evaluating circulating tumor ctDNA in patients receiving adjuvant atezolizumab in high-risk muscle-invasive urothelial cancer after surgery was presented at the European Society of Medical Oncology Immuno-Oncology Virtual Congress in 2020.
Read More
Low-Dose Chemotherapy With Immunotherapy Shows Efficacy in UC
August 3rd 2021In an interview with Targeted Oncology™, Rhonda L. Bitting, MD, discussed the efficacy results and key takeaways of a study investigating low-dose paclitaxel plus pembrolizumab in patients with platinum-refractory UC.
Read More
Sapanisertib Not Active in Patients With TSC1/TSC2-Mutated mUC
August 2nd 2021In an interview with Targeted Oncology™, Joseph Kim, MD, an associate professor of internal medicine at the Yale School of Medicine, discuss the lack of clinical benefit of sapanisertib for the treatment of TSC1/TSC2mutated mUC.
Read More
High Urinary Cotinine Levels Correlate With Recurrence of Non-Muscle Invasive Bladder Cancer
July 14th 2021A significant increase in the risk of disease recurrence among patients with high level of the nicotine metabolite, urinary cotinine, who had non–muscle invasive bladder cancer and were smokers.
Read More
Roundtable Discussion: Defining How the JAVELIN Trial Changes Practice in Metastatic Bladder Cancer
July 9th 2021During a Targeted Oncology Case-Based Roundtable event, Daniel A. Landau, MD, moderated a discussion around the JAVELIN trial and how its results were practice changing for oncologists treating for bladder cancer.
Read More
ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program
June 16th 2021An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.
Read More
INTACT Regimen Does Not Increase Toxicity in Patients With MIBC
June 10th 2021In an interview with Targeted Oncology, Parminder Singh, MD, discussed the need for bladder-sparing therapies in an older patient population of muscle-invasive bladder cancer and the findings from the INTACT clinical trial.
Read More